Free Trial

Phibro Animal Health (PAHC) Competitors

Phibro Animal Health logo
$39.72 +1.15 (+2.98%)
Closing price 10/17/2025 04:00 PM Eastern
Extended Trading
$39.78 +0.06 (+0.16%)
As of 10/17/2025 06:25 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PAHC vs. CRSP, NUVL, AXSM, LEGN, TGTX, PCVX, MTSR, KRYS, PTCT, and ARWR

Should you be buying Phibro Animal Health stock or one of its competitors? The main competitors of Phibro Animal Health include CRISPR Therapeutics (CRSP), Nuvalent (NUVL), Axsome Therapeutics (AXSM), Legend Biotech (LEGN), TG Therapeutics (TGTX), Vaxcyte (PCVX), Metsera (MTSR), Krystal Biotech (KRYS), PTC Therapeutics (PTCT), and Arrowhead Pharmaceuticals (ARWR). These companies are all part of the "pharmaceutical products" industry.

Phibro Animal Health vs. Its Competitors

CRISPR Therapeutics (NASDAQ:CRSP) and Phibro Animal Health (NASDAQ:PAHC) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

CRISPR Therapeutics has a beta of 1.84, suggesting that its stock price is 84% more volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500.

Phibro Animal Health has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CRISPR Therapeutics$35M179.69-$366.25M-$5.43-12.73
Phibro Animal Health$1.30B1.24$48.26M$1.1833.66

In the previous week, CRISPR Therapeutics had 24 more articles in the media than Phibro Animal Health. MarketBeat recorded 29 mentions for CRISPR Therapeutics and 5 mentions for Phibro Animal Health. CRISPR Therapeutics' average media sentiment score of 0.74 beat Phibro Animal Health's score of 0.24 indicating that CRISPR Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CRISPR Therapeutics
12 Very Positive mention(s)
4 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Phibro Animal Health
1 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

CRISPR Therapeutics currently has a consensus target price of $72.59, suggesting a potential upside of 4.97%. Phibro Animal Health has a consensus target price of $28.40, suggesting a potential downside of 28.50%. Given CRISPR Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CRISPR Therapeutics is more favorable than Phibro Animal Health.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CRISPR Therapeutics
2 Sell rating(s)
7 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.42
Phibro Animal Health
2 Sell rating(s)
4 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.13

69.2% of CRISPR Therapeutics shares are held by institutional investors. Comparatively, 99.3% of Phibro Animal Health shares are held by institutional investors. 4.3% of CRISPR Therapeutics shares are held by company insiders. Comparatively, 50.1% of Phibro Animal Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Phibro Animal Health has a net margin of 3.73% compared to CRISPR Therapeutics' net margin of -1,229.43%. Phibro Animal Health's return on equity of 32.14% beat CRISPR Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CRISPR Therapeutics-1,229.43% -20.05% -17.09%
Phibro Animal Health 3.73%32.14%6.89%

Summary

Phibro Animal Health beats CRISPR Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Phibro Animal Health News Delivered to You Automatically

Sign up to receive the latest news and ratings for PAHC and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PAHC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PAHC vs. The Competition

MetricPhibro Animal HealthMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$1.61B$10.94B$6.21B$10.54B
Dividend Yield1.24%1.88%5.70%4.80%
P/E Ratio33.6621.0385.7027.13
Price / Sales1.2426.43581.70177.21
Price / Cash12.1524.5537.1060.81
Price / Book5.633.4112.236.52
Net Income$48.26M$210.63M$3.33B$276.93M
7 Day Performance9.15%0.03%1.17%1.93%
1 Month Performance-0.35%-0.54%6.85%2.19%
1 Year Performance65.02%-9.78%58.93%34.62%

Phibro Animal Health Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PAHC
Phibro Animal Health
3.9573 of 5 stars
$39.72
+3.0%
$28.40
-28.5%
+65.0%$1.61B$1.30B33.662,475Analyst Forecast
CRSP
CRISPR Therapeutics
2.2308 of 5 stars
$70.19
+3.6%
$71.50
+1.9%
+41.4%$6.16B$35M-12.93460Trending News
Analyst Forecast
Insider Trade
Analyst Revision
NUVL
Nuvalent
2.8471 of 5 stars
$83.85
-0.4%
$118.89
+41.8%
-10.8%$6.07BN/A-17.1140Trending News
Analyst Forecast
Insider Trade
Analyst Revision
AXSM
Axsome Therapeutics
4.7333 of 5 stars
$119.94
-0.3%
$177.93
+48.4%
+37.1%$6.00B$495.03M-23.66380Positive News
Analyst Revision
LEGN
Legend Biotech
3.0853 of 5 stars
$31.44
-1.9%
$74.22
+136.1%
-25.4%$5.92B$627.24M-35.732,609News Coverage
Analyst Forecast
TGTX
TG Therapeutics
4.5107 of 5 stars
$36.76
+0.1%
$49.00
+33.3%
+48.7%$5.82B$454.07M99.35290Positive News
PCVX
Vaxcyte
2.3414 of 5 stars
$41.21
-3.4%
$106.25
+157.8%
-63.3%$5.54BN/A-10.03160News Coverage
Analyst Forecast
MTSR
Metsera
N/A$52.50
+1.2%
$55.75
+6.2%
N/A$5.45BN/A0.0081
KRYS
Krystal Biotech
4.7752 of 5 stars
$180.57
-1.5%
$209.00
+15.7%
+6.2%$5.31B$359.21M36.70210News Coverage
Analyst Forecast
Gap Up
PTCT
PTC Therapeutics
3.357 of 5 stars
$64.80
-0.9%
$69.00
+6.5%
+68.7%$5.19B$1.76B9.301,410Analyst Revision
ARWR
Arrowhead Pharmaceuticals
3.8755 of 5 stars
$37.50
+3.8%
$43.14
+15.0%
+73.8%$4.99B$3.55M-29.30400

Related Companies and Tools


This page (NASDAQ:PAHC) was last updated on 10/19/2025 by MarketBeat.com Staff
From Our Partners